BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully subcutaneous dose regimen

  October 27, 2025

   · 

  19 min read
• Press Releases

  Lilly’s baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

  October 27, 2025

   · 

  18 min read
• Press Releases

  Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

  October 27, 2025

   · 

  15 min read
• Press Releases

  Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

  October 27, 2025

   · 

  7 min read
• Press Releases

  Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

  October 27, 2025

   · 

  7 min read
• Press Releases

  MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

  October 27, 2025

   · 

  6 min read
• Press Releases

  Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

  October 27, 2025

   · 

  8 min read
• Press Releases

  ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

  October 27, 2025

   · 

  1 min read
• Press Releases

  Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

  October 27, 2025

   · 

  3 min read
• Press Releases

  U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study

  October 27, 2025

   · 

  11 min read